A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening
autoimmune disorder that is characterized by mucocutaneous blisters.Abatacept is a biologic
drug that belongs to the class of T-cell co-stimulation modulators and is used for the
treatment of autoimmune diseases.
Phase:
Phase 4
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Wuhan Central Hospital Wuhan Hospital of Traditional Chinese Medicine